Stevanato Group (STVNN) Stock Price & Analysis
STVNN Stock Chart & Stats
- Day’s Range
- MXN 349.52 - MXN 349.52
- 52-Week Range
- MXN 246.00 - MXN 444.62
- Previous Close
- MXN 349.52
- Volume
- 0
- Average Volume (3M)
- 0
- Market Cap
- MXN 99.43B
- Enterprise Value
- MXN 5.35B
- Total Cash (Recent Filing)
- MXN 83.58M
- Total Debt (Recent Filing)
- MXN 442.99M
- Price to Earnings (P/E)
- 36.0
- Beta
- 0.04
- Next Earnings
- Nov 03, 2026 (Est.)
- EPS Estimate
- 3.29
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 0.30%
Bulls Say, Bears Say
Bulls Say
High-value Solutions Growth
Rapid growth in high-value solutions is improving Stevanato’s mix toward premium biologics and delivery products. A larger contribution from these offerings can support stronger customer relationships, differentiated capabilities, and more resilient revenue quality as injectable therapies scale.
Profitability And Margin Expansion
The combination of faster EBITDA growth and meaningful margin expansion indicates operating leverage and improving execution. If supported by the company’s richer product mix and capacity investments, higher profitability should strengthen internal funding capacity and earnings durability.
Product Innovation And Commercial Traction
European approvals for a therapy using the proprietary Alina pen provide evidence that Stevanato’s delivery technology is progressing from development into commercial use. Expected production in Germany and anticipated double-digit growth could deepen customer integration and expand future platform revenue.
Bears Say
Weak Free-cash-flow Conversion
Positive operating cash flow is not consistently translating into free cash flow because capital spending and working-capital needs absorb substantial cash. Persistent volatility could reduce financial flexibility and constrain the company’s ability to fund expansion without relying more heavily on debt.
Engineering Revenue And Timing Pressure
Longer sales cycles and project phasing make Engineering revenue less predictable and can delay conversion of new orders into cash and earnings. Management expects the segment to decline mid-single digits to low-double digits, creating a continuing offset to BDS growth.
Margin And Cost Headwinds
Although current profitability is solid, the longer-term decline from earlier margin levels suggests that cost inflation, investment-related depreciation, currency effects, or mix pressure may limit expansion. Higher taxes and operating costs could keep earnings growth below revenue growth.
Stevanato Group News
STVNN FAQ
What was Stevanato Group’s price range in the past 12 months?
What is Stevanato Group’s market cap?
When is Stevanato Group’s upcoming earnings report date?
How were Stevanato Group’s earnings last quarter?
Is Stevanato Group overvalued?
Does Stevanato Group pay dividends?
What is Stevanato Group’s EPS estimate?
How many shares outstanding does Stevanato Group have?
What happened to Stevanato Group’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Stevanato Group?
What is the TipRanks Smart Score and how is it calculated?
Stevanato Group Stock Smart Score
Company Description
Stevanato Group
Stevanato Group S.p.A. is dedicated to engineering, manufacturing, and distributing integrated solutions for the pharmaceutical and healthcare sectors. Its core offerings span a wide array of products, including containment solutions, drug delivery systems, and medical devices, alongside diagnostic and analytical support. The company also produces specialized machinery for tasks such as visual inspection, assembly, packaging, and glass formation. Established in 1949, the company's main operations are situated in Piombino Dese, Italy, functioning as a subsidiary of Stevanato Holding S.R.L.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Franco Stevanato
- Employees
- 6,010
- Website
- www.stevanatogroup.com
- Address
- Via Molinella, 17, Piombino Dese, PD, 35017, IT
Stevanato Group (STVNN) Earnings & Revenues
STVNN Company Deck
STVNN Earnings Call
Earnings Call SentimentPositive
The call presented a generally constructive operational and commercial story: top-line growth (8% y/y), strong expansion of high-value solutions (+16%) and significant adjusted EBITDA and margin improvement. The company announced an important commercial milestone (Alina approvals) and ongoing capacity build-outs that support mid- to long-term value capture in biologics. Offsetting these positives were one-time divestiture costs (EUR 12.2m), negative free cash flow in the quarter, elevated net debt, higher taxes, and caution around elongated sales cycles in Engineering. On balance, the highlights — recurring revenue growth, margin expansion, product approvals and clear capacity investments — outweigh the near-term lowlights tied largely to one-time items and measured execution/timing risks.
View all MX:STVNN earnings summariesSTVNN Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 12 | 2 | 6 |
| Technical Analysis | 2 | 2 | 4 |
| Moving Averages | 10 | 0 | 2 |









